Acetaldehyde Acetone Amaryllis Belladonna Whole Be

證據等級: L5

預測適應症: 0 個

Multi-Component Mixture (15 Ingredients): No Repurposing Prediction Available

One-Sentence Summary

This submission contains a complex 15-component mixture including several inherently toxic substances (e.g., benzene, strychnos nux-vomica seed, colchicum autumnale bulb, phosphorus). The TxGNN model returned no predicted new indications for this combination, and the mixture holds no regulatory approval in any queried jurisdiction. Given the complete absence of predictions and pervasive data gaps, this candidate cannot be evaluated under the standard repurposing framework.

Quick Overview

Item	Content
Original Indication	Unknown — no regulatory records found
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	N/A
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN prediction is available for this candidate; therefore, a mechanistic rationale for repurposing cannot be constructed.

The 15 listed components span radically different chemical classes: industrial solvents and reactive species (acetaldehyde, acetone, benzene), plant-derived alkaloid sources (strychnos nux-vomica seed, colchicum autumnale bulb, schoenocaulon officinale seed, amaryllis belladonna whole), aromatic/essential oil constituents (eugenol, cananga odorata leaf oil, citrus aurantium flower oil, cinnamic acid), a functional phytochemical (indole-3-carbinol), and inorganic/mineral substances (phosphorus, sulfur iodide, liquid petroleum). Several of these are acutely toxic or regulated as hazardous materials in most jurisdictions.

Without a coherent shared pharmacological mechanism, no disease-indication link can be proposed and no repurposing hypothesis can be evaluated at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

This mixture holds no US FDA-approved product records and is not marketed. No license table can be generated.

Safety Considerations

Several components of this mixture carry well-documented toxicity profiles that warrant immediate attention:

BENZENE: IARC Group 1 human carcinogen; causes aplastic anemia, acute myeloid leukemia, and chromosomal damage with chronic exposure.
STRYCHNOS NUX-VOMICA SEED: Contains strychnine and brucine — potent competitive glycine antagonists; extremely narrow therapeutic index, high fatality risk in overdose.
COLCHICUM AUTUMNALE BULB: Source of colchicine; associated with severe gastrointestinal toxicity, bone marrow suppression, and multi-organ failure in overdose.
SCHOENOCAULON OFFICINALE SEED: Contains veratrum alkaloids (cevadine, veratridine); cardiovascular collapse and neurotoxicity risks.
PHOSPHORUS: Systemic hepatotoxin and nephrotoxin at low doses; burns tissue on contact.
LIQUID PETROLEUM: Not intended for internal therapeutic use; significant aspiration pneumonia risk.
SULFUR IODIDE: Corrosive and reactive; formal therapeutic safety data is absent.

Formal drug–drug interaction data and structured contraindication records are not available in queried databases for this multi-ingredient combination.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate returns no TxGNN repurposing predictions and carries zero regulatory approval in any queried jurisdiction. Multiple components are classified as known toxins, carcinogens, or hazardous substances, making a favorable benefit–risk profile implausible without extraordinary evidence and a clearly defined therapeutic context.

To proceed, the following is needed:

Clarify the intended product category: homeopathic preparation, traditional medicine, industrial compound, or research mixture — as each follows a different regulatory and evaluation pathway
Provide dosage form and per-ingredient concentration data, since toxicological risk is heavily concentration-dependent (e.g., colchicine at homeopathic dilution vs. pharmacological dose)
Commission a formal toxicology review given the presence of benzene, strychnine-containing seeds, colchicum alkaloids, and elemental phosphorus
If a legitimate therapeutic claim exists, retrieve the full package insert, historical indication records, and MOA data from the originating regulatory authority
Re-submit individual active ingredient INN codes (rather than the full concatenated string) to the TxGNN pipeline to obtain component-level repurposing predictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.